Prothena (PRTA) News Today → 4 Cryptos BETTER than Bitcoin (From True Market Insiders) (Ad) Free PRTA Stock Alerts $22.52 -0.87 (-3.72%) (As of 05/17/2024 08:54 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14, 2024 | finance.yahoo.comNews Flash: Analysts Just Made A Notable Upgrade To Their Prothena Corporation plc (NASDAQ:PRTA) ForecastsMay 13, 2024 | americanbankingnews.comBrokers Issue Forecasts for Prothena Co. plc's Q3 2024 Earnings (NASDAQ:PRTA)May 12, 2024 | finance.yahoo.comAnalysts Have Lowered Expectations For Prothena Corporation plc (NASDAQ:PRTA) After Its Latest ResultsMay 12, 2024 | americanbankingnews.comLeerink Partnrs Weighs in on Prothena Co. plc's FY2028 Earnings (NASDAQ:PRTA)May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Prothena Amid Strong Pipeline and Financial HealthMay 10, 2024 | marketbeat.comLeerink Partnrs Comments on Prothena Co. plc's FY2028 Earnings (NASDAQ:PRTA)Prothena Co. plc (NASDAQ:PRTA - Free Report) - Stock analysts at Leerink Partnrs lowered their FY2028 earnings per share estimates for Prothena in a research note issued to investors on Wednesday, May 8th. Leerink Partnrs analyst R. Li now expects that the biotechnology company will post earningsMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed: Prothena’s Prasinezumab Shows Promise in Slowing Parkinson’s ProgressionMay 9, 2024 | marketbeat.comProthena (NASDAQ:PRTA) PT Lowered to $84.00 at HC WainwrightHC Wainwright reduced their target price on Prothena from $90.00 to $84.00 and set a "buy" rating on the stock in a report on Thursday.May 9, 2024 | marketbeat.comProthena (NASDAQ:PRTA) Issues Quarterly Earnings Results, Misses Estimates By $0.13 EPSProthena (NASDAQ:PRTA - Get Free Report) issued its quarterly earnings data on Wednesday. The biotechnology company reported ($1.34) earnings per share for the quarter, missing analysts' consensus estimates of ($1.21) by ($0.13). Prothena had a negative net margin of 160.91% and a negative return on equity of 24.84%. During the same period last year, the business posted ($0.89) EPS.May 9, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Paragon 28 (FNA), Prothena (PRTA)May 8, 2024 | investorplace.comPRTA Stock Earnings: Prothena Corp Misses EPS, Misses Revenue for Q1 2024May 8, 2024 | tmcnet.comProthena Reports First Quarter 2024 Financial Results and Business HighlightsMay 8, 2024 | finance.yahoo.comWe think Prothena Corporation plc's (NASDAQ:PRTA) CEO May Struggle To See Much Of A Pay Rise This YearMay 7, 2024 | msn.comProthena Q1 2024 Earnings PreviewMay 7, 2024 | markets.businessinsider.comProthena is about to announce its earnings — here's what to expectMay 2, 2024 | marketbeat.comProthena (PRTA) Set to Announce Quarterly Earnings on WednesdayProthena (NASDAQ:PRTA) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports.May 1, 2024 | stockhouse.comProthena to Report First Quarter 2024 Financial Results on May 8April 26, 2024 | nasdaq.comCommit To Buy Prothena Corp At $15, Earn 21.3% Using OptionsApril 24, 2024 | marketbeat.comProthena (NASDAQ:PRTA) Reaches New 1-Year Low at $20.32Prothena (NASDAQ:PRTA) Hits New 12-Month Low at $20.32April 17, 2024 | investing.comProthena reports potential AL amyloidosis treatmentApril 16, 2024 | marketbeat.comProthena (NASDAQ:PRTA) Reaches New 1-Year Low at $21.31Prothena (NASDAQ:PRTA) Sets New 1-Year Low at $21.31April 15, 2024 | businesswire.comProthena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & LymphomaApril 12, 2024 | marketbeat.comLeerink Partnrs Weighs in on Prothena Co. plc's Q1 2024 Earnings (NASDAQ:PRTA)Prothena Co. plc (NASDAQ:PRTA - Free Report) - Stock analysts at Leerink Partnrs lowered their Q1 2024 EPS estimates for shares of Prothena in a report issued on Tuesday, April 9th. Leerink Partnrs analyst R. Li now forecasts that the biotechnology company will post earnings per share of ($1.14)April 11, 2024 | marketbeat.comProthena (NASDAQ:PRTA) Trading Up 3.7%Prothena (NASDAQ:PRTA) Trading Up 3.7%April 10, 2024 | marketbeat.comProthena (NASDAQ:PRTA) Stock Rating Reaffirmed by Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating on shares of Prothena in a research report on Wednesday.April 10, 2024 | marketbeat.comProthena (NASDAQ:PRTA) Hits New 12-Month Low at $21.91Prothena (NASDAQ:PRTA) Hits New 12-Month Low at $21.91April 4, 2024 | marketbeat.comProthena (NASDAQ:PRTA) Stock Price Down 3%Prothena (NASDAQ:PRTA) Trading Down 3%April 3, 2024 | marketbeat.comProthena (NASDAQ:PRTA) Sets New 12-Month Low at $23.41Prothena (NASDAQ:PRTA) Hits New 1-Year Low at $23.41April 2, 2024 | marketbeat.comProthena (NASDAQ:PRTA) Shares Gap Down to $26.15Prothena (NASDAQ:PRTA) Shares Gap Down to $26.15April 1, 2024 | marketbeat.comProthena Co. plc (NASDAQ:PRTA) Given Average Rating of "Moderate Buy" by BrokeragesShares of Prothena Co. plc (NASDAQ:PRTA - Get Free Report) have been given a consensus rating of "Moderate Buy" by the nine ratings firms that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation oMarch 28, 2024 | marketbeat.comProthena (NASDAQ:PRTA) Trading Down 2.3%Prothena (NASDAQ:PRTA) Shares Down 2.3%March 25, 2024 | marketbeat.comProthena Co. plc (NASDAQ:PRTA) Shares Purchased by SG Americas Securities LLCSG Americas Securities LLC increased its position in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 46.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 135,857 shares of the biotechnoloMarch 18, 2024 | marketbeat.comProthena (NASDAQ:PRTA) Stock Price Down 4.9%Prothena (NASDAQ:PRTA) Trading Down 4.9%March 18, 2024 | marketbeat.comProthena Co. plc (NASDAQ:PRTA) Shares Sold by Wellington Management Group LLPWellington Management Group LLP reduced its stake in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 3.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,141,647 shares of the bioteMarch 13, 2024 | markets.businessinsider.comDemystifying Prothena Corp: Insights From 8 Analyst ReviewsMarch 11, 2024 | marketbeat.comProthena Co. plc Forecasted to Post FY2026 Earnings of ($4.63) Per Share (NASDAQ:PRTA)Prothena Co. plc (NASDAQ:PRTA - Free Report) - Research analysts at Zacks Research issued their FY2026 EPS estimates for shares of Prothena in a report issued on Thursday, March 7th. Zacks Research analyst E. Bagri forecasts that the biotechnology company will post earnings of ($4.63) per share fMarch 8, 2024 | marketbeat.comQube Research & Technologies Ltd Buys 43,256 Shares of Prothena Co. plc (NASDAQ:PRTA)Qube Research & Technologies Ltd boosted its holdings in Prothena Co. plc (NASDAQ:PRTA - Free Report) by 104.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 84,653 shares of the biotechnology company'sMarch 7, 2024 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Prothena (PRTA)March 7, 2024 | marketbeat.comProthena Co. plc (NASDAQ:PRTA) Receives Average Recommendation of "Moderate Buy" from BrokeragesProthena Co. plc (NASDAQ:PRTA - Get Free Report) has received an average rating of "Moderate Buy" from the nine brokerages that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and seven have issued a buy recommendatioMarch 5, 2024 | businesswire.comProthena to Participate in Upcoming Healthcare ConferencesMarch 4, 2024 | finance.yahoo.comProthena Appoints David Ford to Newly Created Chief People Officer PositionMarch 2, 2024 | marketbeat.comTrexquant Investment LP Acquires Shares of 56,843 Prothena Co. plc (NASDAQ:PRTA)Trexquant Investment LP acquired a new stake in Prothena Co. plc (NASDAQ:PRTA - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 56,843 shares of the biotechnology company'March 1, 2024 | finance.yahoo.comProthena Corporation plc (PRTA)February 28, 2024 | marketbeat.com28,000 Shares in Prothena Co. plc (NASDAQ:PRTA) Acquired by Algert Global LLCAlgert Global LLC bought a new position in Prothena Co. plc (NASDAQ:PRTA - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 28,000 shares of the biotechnology company's stock, valued at approximately $1,351,0February 26, 2024 | marketbeat.comHealthcare of Ontario Pension Plan Trust Fund Invests $1.47 Million in Prothena Co. plc (NASDAQ:PRTA)Healthcare of Ontario Pension Plan Trust Fund bought a new position in Prothena Co. plc (NASDAQ:PRTA - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 30,500 shares of the biotechnology company's stock, valued at aFebruary 25, 2024 | marketbeat.comMariner LLC Acquires 32,870 Shares of Prothena Co. plc (NASDAQ:PRTA)Mariner LLC boosted its holdings in Prothena Co. plc (NASDAQ:PRTA - Free Report) by 24.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 167,932 shares of the biotechnology company's stock after purchasing anFebruary 23, 2024 | seekingalpha.comProthena: Alzheimer's Data Update In 2024 Could Move The NeedleFebruary 22, 2024 | marketbeat.comProthena Co. plc Expected to Post FY2024 Earnings of ($4.61) Per Share (NASDAQ:PRTA)Prothena Co. plc (NASDAQ:PRTA - Free Report) - Analysts at Cantor Fitzgerald issued their FY2024 EPS estimates for Prothena in a research note issued to investors on Monday, February 19th. Cantor Fitzgerald analyst C. Duncan anticipates that the biotechnology company will earn ($4.61) per share fFebruary 22, 2024 | marketbeat.comCitigroup Inc. Purchases 20,378 Shares of Prothena Co. plc (NASDAQ:PRTA)Citigroup Inc. boosted its position in Prothena Co. plc (NASDAQ:PRTA - Free Report) by 42.9% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 67,930 shares of the biotechnology company's stock after purchasing an additional 20,378 shares during the pFebruary 21, 2024 | msn.comProthena appoints Daniel G. Welch as Chair Designate Get Prothena News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Shocking $16T Elon Musk Crypto Leak (Ad)Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run. Click here now to get your copy. PRTA Media Mentions By Week PRTA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRTA News Sentiment▼0.330.42▲Average Medical News Sentiment PRTA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRTA Articles This Week▼53▲PRTA Articles Average Week Get Prothena News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Enliven Therapeutics News Today AbCellera Biologics News Today Verona Pharma News Today Collegium Pharmaceutical News Today Mirum Pharmaceuticals News Today Ironwood Pharmaceuticals News Today Innoviva News Today Cassava Sciences News Today Belite Bio News Today MannKind News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRTA) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaNext President (Not Trump. Not Biden.)The Freeport SocietyUrgent Nvidia WarningAltimetryElon’s New Device is About to Shock the WorldInvestorPlace"The Biggest Drug Ever" Is ComingBehind the MarketsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prothena Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
